Search
for
Sort by
Research 30 of 57
- Dermatologic adverse events associated with afatinib: an oral ErbB family blocker
- Periocular Manifestations of Afatinib Therapy
- Erosive Pustular Dermatosis of the Scalp Due to Afatinib: A Rare Case
- Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System
- EGFR inhibitor-induced folliculitis decalvans: a case series and management guidelines
- Dermatologic adverse events in EGFR-TKIs: A real-world analysis.
- Drug Repurposing against KRAS Mutant G12C: A Machine Learning, Molecular Docking, and Molecular Dynamics Study
- Target-Adverse Events and Fear of Cancer Progression, Anxiety, and Depression in Patients with Advanced Non-Small Cell Lung Cancer
- Dermatologic Reactions to Targeted Therapy
- Management of Toxicities of Targeted Therapies
- Index
- Dasatinib-Induced Leukotrichia in a Patient With Chronic Myelogenous Leukemia
- Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
- Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer
- Hair disorders in patients with cancer
- Alopecia in patients treated with molecularly targeted anticancer therapies
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Alopecia in Association with Malignancy: A Review
- Dermatologic Adverse Events from Cancer Treatments
- Targeted Treatments of Non-Small Cell Lung Cancer (NSCLC): Skin Toxicity
- Adverse Hair Reactions to New Targeted Therapies for Cancer
- The pharmacovigilance analysis of adverse events of erlotinib based on the open access FAERS database
- Flexural Agminated Eruptive Nevi in Langerhans Cell Histiocytosis
- Tyrosine Kinase Inhibitors against Cancer: Their Safety in 216 Moroccan Patients
- Epidermal Growth Factor Receptor Inhibitors: A Review of Cutaneous Adverse Events and Management
- EGFR Inhibitors and Cutaneous Complications: A Practical Approach to Management
- Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities
- Efficacy and patient-reported outcomes in advanced non-small cell lung cancer patients receiving aumolertinib as first-line therapy: a real-world study
- Cutaneous Adverse Effects of EGFR Therapy in Breast Cancer Treatment
- Review of Drug Repositioning in Cancer Therapeutics